⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533321 | 0.82 | — | — | |
| SCHEMBL9681866 | 0.81 | — | — | |
| SCHEMBL6622603 | 0.81 | — | — | |
| SCHEMBL16799711 | 0.80 | — | — | |
| SCHEMBL2004909 | 0.78 | — | — | |
| SCHEMBL16799785 | 0.78 | ALDH1A1 (0.48) | — | |
| SCHEMBL2010715 | 0.75 | — | — | |
| SCHEMBL689173 | 0.73 | — | — | |
| SCHEMBL727664 | 0.71 | — | — | |
| SCHEMBL19546253 | 0.69 | DRD2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077387-B1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | claimed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | claimed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | claimed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | claimed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | claimed |
| US-11672780-B2 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3478682-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| EP-3478682-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3143023-B1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | ABBVIE DEUTSCHLAND (DE) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018005586-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| US-9527856-B2 | Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | disclosed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-03 | — | — | US | disclosed |
| WO-2015173392-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |